Using low-level laser therapy to prevent mouth sores in young cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of low-level laser therapy (LLLT) in preventing severe oral mucositis in children and young adults undergoing high-risk chemotherapy regimens. Participants aged 4 to 25 years, who are free of mucositis at the start of treatment, will receive either LLLT or a placebo during their chemotherapy. The study aims to determine if LLLT can significantly reduce the incidence of grade 3-4 mucositis, which can cause severe pain and complications during cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 4 and ≤ 25 years
2. No mucositis or other mouth lesions at the beginning of chemotherapy that could prevent the laser session and chemotherapy
3. Cooperative patient, able to wear black glasses and to sit with his open mouth during laser session
4. Patients treated in one of the SFCE centers that participate to the study
5. Patients undergoing chemotherapy course with high risk of severe mucositis :

   1. high-dose chemotherapy with hematological stem cell transplantation (stratum A) including but not limited to 8 HDC conditioning regimens for solid tumors intensive treatment (Busilvex-Melphalan, VP16-Thiotepa, BAM, BEAM, Thiotepa 900mg/m\^2, Carboplatine-Thiotepa (typical teratoid rhabdoid tumor or medulloblastoma), VP16-Carboplatine-Thiotepa, Endoxan-Busilvex and VP16 - Melphalan) and 5 myeloablative conditioning regimens (for example : TBI-VP16, Busilvex-Endoxan-Thiotepa, Busilvex-Endoxan+/-Melphalan and Thiotepa-Busulfan-Fludarabine),
   2. Conventional chemotherapy courses (stratum B) but not limited to COPADM (B lymphoma), CAV/ICE (plexus choroid carcinoma or B lymphoma), Head start induction course (medulloblastoma), N6 course (neuroblastoma), VIDE or VCD (Ewing sarcoma), API/AP (osteosarcoma), Cyclophosphamide and Doxorubicine (nephroblastoma), PLADO/Carboplatine and Doxorubicine (hepatoblastoma), IVADo (rhabdomyosarcoma), induction and consolidation of the Myechild protocol (Cytarabine/Mithoxantrone Fludarabine Aractine +/- Darubicine) (acute myeloid leukemia) and 5FU-cisplatine (undifferentiated carcinoma of nasopharyngeal),
   3. Others courses of chemotherapy (stratum A or B) which may cause mucositis can be considered (please refer to the non-inclusion criterion n° 5 to see the prohibited chemotherapy list). In this case, the coordinating investigator approval is required.
6. Women of childbearing potential must have a negative serum β-HCG pregnancy test prior to the administration of the first laser treatment.
7. French speaking patients
8. Patient and/or parents/legal representatives should understand, sign, and date the written informed consent form prior to any protocol specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
9. Patients must be affiliated to a social security regimen or beneficiary of the same

NB : all patients who respect all the eligibility criteria are recruitable even if the patient haven't a cancer (Patients undergoing a chemotherapy with high risk of severe mucositis for another clinical reason than cancer).

Exclusion Criteria:

1. Treatment by opioids on daily basis
2. Orthodontic appliance
3. Pregnant or breastfeeding young ladies or women
4. Patients with cognitive disorder who could not self-evaluate his pain or with a mucositis difficult to evaluate
5. None of this chemotherapy is allowed : Methotrexate, VA or VAD (nephroblastoma), Carboplatine - Etoposide (3 or 5 days), Temozolomide single agent or in combination with Topotecan/Irinotecan or Bevacizumab, Gemzar, Taxotere, Ifosfamide - Etoposide (Ewing sarcoma), OEPA, COPDAC, IgEV (Hodgkin lymphoma)

Where it's running

• Gustave Roussy
  Villejuif, Val de Marne, France Recruiting
• Centre Oscar Lambret
  Lille, France Recruiting
• Hôpital Robert Debré
  Paris, France Recruiting
• Institut Curie
  Paris, France Recruiting
• CHU de Rennes
  Rennes, France Recruiting

Study contacts

• Study coordinator: Léa Guerrini-Rousseau, MD
• Email: lea.guerrini-rousseau@gustaveroussy.fr
• Phone: +33 (0)1 42 11 67 41

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Copaiba Mouthwash with Low-Level Laser Therapy to Prevent Mouth Sores After Stem Cell Transplant

  This phase 2 trial tests whether a copaíba-based mouthwash, used four times daily, can help prevent oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation.

  Recruiting Phase 2 Instituto Nacional de Cancer, Brazil · Rio de Janeiro, Rio de Janeiro · NCT07810530

• Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant

  This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07709195

• BupiZenge vs Lidocaine for mouth pain from oral mucositis in head and neck cancer

  A phase 3 trial tests whether the BupiZenge lozenge provides better pain relief than lidocaine for mouth sores caused by radiation in head and neck cancer patients.

  Recruiting at 9 sites Phase 3 OncoZenge AB · Copenhagen and 10 other locations · NCT07672236

• Ozone gas plus biomimetic toothpaste and mouthwash to treat cancer therapy mouth sores

  This trial will test whether adding a biomimetic toothpaste and mouthwash to ozone gas therapy helps adults with chemo- or radiotherapy-induced mouth sores heal faster and have less pain.

  Recruiting University of Pavia · Pavia, Lombardy · NCT07491536

• High-level laser therapy for oral mucositis in children receiving hematopoietic stem cell transplant

  This trial tests whether high-level laser therapy can reduce the pain and severity of oral mucositis in children undergoing hematopoietic stem cell (bone marrow) transplantation.

  Recruiting Ain Shams University · Cairo, Cairo Governorate · NCT07436650

• Amimestrocel infusion to prevent severe mouth sores after allogeneic stem cell transplant

  This study will try a single IV infusion of Amimestrocel in adults receiving myeloablative allogeneic stem cell transplants with TBI or melphalan to see if it prevents severe mouth sores.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhu, Jiangsu · NCT07400328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.